On August 7, Monster Beverage fell 3.45% in regular trading, trading around $90.65/share with turnover of $118 million. The decline came despite a Q2 earnings beat released the prior evening.
Monster Beverage reported Q2 adjusted EPS of $0.60, exceeding the consensus estimate of $0.58, while revenue of $2.54 billion grew 20.4% year-over-year and topped the $2.43 billion expectation. Despite the double beat, the stock sold off as investors focused on forward headwinds. UBS had previously highlighted that the company faces tougher year-over-year comparisons in H2, a slower new product cadence, and a stretched valuation that could make further share price appreciation difficult. Morgan Stanley raised its target price to $110 from $103 post-earnings while maintaining an Overweight rating, but market sentiment remained dominated by concerns over decelerating medium-term growth momentum. Additionally, a coalition including Monster Beverage is lobbying regulators for a one-year extension on labeling changes, citing millions of units in existing inventory.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments